Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

309
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
309
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

223
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
223
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

414
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
414
Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

312
Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
312
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

236
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
236

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.

ESMO open·2024
Same author

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF<sup>V600</sup>-mutated melanoma.

ESMO open·2023
Same author

Performance evaluation of a 3D-printed sharp-cut cyclone.

Environmental science. Processes & impacts·2022
Same author

Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188].

European journal of cancer (Oxford, England : 1990)·2022
Same author

De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.

European journal of cancer (Oxford, England : 1990)·2021

Related Experiment Video

Updated: Jan 9, 2026

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

3.4K

Advancing Drug Risk Assessment with Tissue Models: Correlating QT Interval and APD90 Prolongation to Refine

M Costi, J M Ferrero, J F Rordriguez Matas

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
    |December 3, 2025
    PubMed
    Summary

    A new tissue model accurately predicts drug-induced arrhythmias by measuring action potential duration at 90% repolarization (APD90) prolongation. This improves upon traditional QT interval assessments for safer drug development.

    More Related Videos

    Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
    09:17

    Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

    Published on: August 9, 2022

    2.5K
    Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
    06:15

    Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

    Published on: August 16, 2024

    758

    Related Experiment Videos

    Last Updated: Jan 9, 2026

    Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
    08:05

    Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

    Published on: June 29, 2022

    3.4K
    Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
    09:17

    Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

    Published on: August 9, 2022

    2.5K
    Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
    06:15

    Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

    Published on: August 16, 2024

    758

    Area of Science:

    • Cardiovascular Pharmacology
    • Electrophysiology
    • Drug Safety Assessment

    Background:

    • Traditional drug arrhythmogenicity assessment relies on QT interval prolongation, which has limitations.
    • Understanding cellular mechanisms is crucial for predicting macroscopic cardiac events.

    Purpose of the Study:

    • To evaluate a tissue model for assessing drug-induced arrhythmogenic potential.
    • To correlate action potential duration at 90% repolarization (APD90) prolongation in tissue with QT interval prolongation.
    • To explore the regulatory implications of using cellular biomarkers for drug safety.

    Main Methods:

    • Utilized a cardiac tissue model to measure electrophysiological parameters.
    • Recorded pseudo-electrocardiograms (pseudo-ECGs) to assess macroscopic behavior.
    • Quantified the median of APD90 prolongation in response to drug stimuli.

    Main Results:

    • Demonstrated a strong correlation between APD90 prolongation in tissue and QT interval prolongation.
    • The tissue model accurately captured biological mechanisms linking cellular dynamics to organ-level function.
    • Pseudo-ECG measurements reflected the influence of cellular changes on overall cardiac electrical activity.

    Conclusions:

    • Tissue models incorporating cellular biomarkers like APD90 prolongation offer a more reliable assessment of drug arrhythmogenicity than isolated cell models or QT interval alone.
    • Integrating APD90 prolongation enhances regulatory review by preserving QT interval information while elucidating underlying mechanisms.
    • This approach supports the development of safer, more effective drugs by improving risk-benefit assessments and enabling personalized therapies.